Divis lab results q4 2021

Divi's Labs soars 4. Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix. Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery.

Mutual Funds. ET TV. More Menu. Earnings season ends today. All News Videos. The company said the net profit was led by new products and base business market share gain in the US, and also new launches and strong volumes in Europe.

Divis lab results q4 2021

Divi's Labs soars 4. Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix. Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery. Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill. India Inc Q2 review: Earnings breadth deteriorates; margin pressure stark. Q3 earnings: Nirmal Bang reviews Glenmark, Divi's results. Pharma Q3: New launches, generic drug demand to aid growth. Cipla Q1 PAT may dip Claris Lifesciences net profit up pc at Rs 35 cr in Q3. Ranbaxy deal to kick in, Halol overhang on Sun Pharma:Brokerages. Good Q3 but Dr Reddy's still far from sustainable growth: Expert. Sun Pharma Q2 show healthy but margins unsustainable: Nangra.

Also, ETMarkets. Exclusive Student Only Offer. Pharma Q3: New launches, generic drug demand to aid growth.

Sales de-grew by Company witnessed revenue contraction for the first time in last 3 years. Source: Consolidated Financials. Divi's Laboratories Ltd. That's all for Divis Labs recommendations.

The Group considered the uncertainty relating to the COVID pandemic in assessing the recoverability of its inventories, receivables and investments. As the Group is into essential manufacturing service, which is exempt from lockdown restrictions, the pandemic did not have any significant impact in its operations or its supply chain, the company added. A part of the project has been completed and became operational and the rest of the capex will be completed during early part of the next financial year. Milestone Alert! Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed — it's all here, just a click away! Login Now!

Divis lab results q4 2021

Choose your reason below and click on the Report button. This will alert our moderators to take action. Log out of your current logged-in account and log in again using your ET Prime credentials to enjoy all member benefits.

Ghost pokemon tattoo

Gold Rate. These 5 Nifty50 stocks are likely to post double-digit profit fall in Q4. Stock Watch. Close Revenues rose Reddy's Laboratories Ltd. Market Classroom. You are already a Moneycontrol Pro user. Market Calendar. India Inc Q2 review: Earnings breadth deteriorates; margin pressure stark. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. Please select a Day. Subscribe to ETPrime. The company said the net profit was led by new products and base business market share gain in the US, and also new launches and strong volumes in Europe.

Choose your reason below and click on the Report button. This will alert our moderators to take action.

Load More. Currency Converter. Claris Lifesciences net profit up pc at Rs 35 cr in Q3. Recommendation breakup is as follows 2 analysts are recommending Strong Buy 4 analysts are recommending to Hold 9 analysts are recommending to Sell 5 analysts are recommending Strong Sell. Good Q3 but Dr Reddy's still far from sustainable growth: Expert. Stock Reports Plus New. Stocks Stock Liveblog. NSE Live Mar 07, You are already a Moneycontrol Pro user. Company recommends a final dividend of Rs 40 per share for the financial year Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill. Commodities Views News. Follow us.